Video summary

삼성바이오로직스 VS 알테오젠, 지금 당장 사야 할 바이오 대장주는? [화려한 썰전 - 소재민 / 테디]

Main summary

Key takeaways

Finance

Finance-focused summary (markets & investing takeaways)

  • The speakers frame the Korean pharma/biotech theme primarily around:
    • CDMO economics
    • U.S.-China geopolitical spillovers
  • They suggest that U.S./China geopolitical pressure can affect Chinese players—e.g., they reference WuXi Biopharmaceuticals facing regulation/sanctions—which they argue can shift demand toward Korean CDMOs.

Who they compare (KOSPI vs KOSDAQ leaders)

  • Samsung Biologics (Samba)

    • Positioned as the KOSPI leader
    • Viewed as a relatively more “stable” CDMO exposure

  • Alteogen (Alte)

    • Positioned as the KOSDAQ leader
    • Framed as more sensitive to KOSDAQ sentiment and “market money flow”

Key caution: valuations are driven by interest-rate expectations

They repeatedly warn that pharma/biotech stock performance is highly influenced by macro / interest-rate expectations, because:

  • Pharma/biotech firms often invest upfront (R&D/technology development) and later receive royalties/returns.
  • When interest rates rise, the cost of capital increases, which can deteriorate sentiment.
  • Even profitable companies may be dragged down by sector-wide rate fears.

Conditional upside scenarios

  • Base case for upside depends on market regime:
    • If KOSDAQ recovers, Alteogen can rebound and participate more strongly.
    • If sector sentiment improves (e.g., rate worries fade), pharma/biotech can regain momentum.

Tickers / assets / instruments mentioned

  • Samsung Biologics (“Samba” / “Samsung Bar”)
  • Alteogen (“Alte” / “Altaengi” / “Alteogen”)
  • Celltrion (compared as a “boring/uninteresting” stock by some investors)
  • WuXi Biopharmaceuticals (China; referenced for sanctions/regulatory pressure)
  • EcoPro BM (secondary battery; mentioned alongside KOSDAQ/sentiment context)
  • Samsung Electronics (capex benchmark)
  • SK Hynix (capex benchmark)
  • Samsung SDI (favorite among “pharma and secondary batteries” in a “Samsung sticker” framing)
  • LNF (mentioned as something the speaker doesn’t like personally, but “discussable”)
  • KOSDAQ / KOSPI indices (market regime drivers)
  • “RT / OTT?”: Appears in the discussion, but the exact instrument/ticker is unclear from the text provided.

Key numbers & thresholds cited

Alteogen technology transfer

  • 4 trillion won

Samsung Biologics rights offering / paid-in capital increase

  • Offering (issuance) price: 1,330,000 KRW
  • Rights offering “success” condition (speaker framing):
    • The stock should hold about 15%–20% above the offering price to qualify as stable/successful
  • Implied “success zone” example:
    • Offering price ~1.33m KRW
    • Roughly 1.55m–1.58m KRW corresponds to ~15%–20% above
  • Reference trading/transfer points mentioned (not perfectly consistent in the subtitles):
    • Trading “around” 1.5m KRW
    • “Transfer” at 1.3m KRW

KOSDAQ level levels (sentiment triggers)

  • Decline to ~600, then recovery to ~800 (as background)
  • They argue KOSDAQ needs to rise another ~50% to reach ~1,250
  • For Alteogen attractiveness, they emphasize KOSDAQ ~870–880 as a sentiment trigger

Portfolio weighting cap (explicit risk management)

  • Pharma/biotech portfolio weight should be <10%
  • Speaker personal example: ~7%
  • They also state that anything above 10% is too aggressive (jokingly framed as “coward”/overly timid—while still emphasizing the explicit cap)

Interest-rate sensitivity

  • No specific yield/level is given, but the rule-of-thumb is:
    • Rate-hike worries emerge → pharma/biotech sells off
    • Rate fears fade → rebound potential increases

Methodology / framework mentioned

1) CDMO-led sector framework tied to geopolitics

  • U.S.-China conflict → regulatory pressure on Chinese pharma
  • That pressure may shift demand toward Korean CDMOs
  • Then evaluate which Korean CDMO has stronger fundamentals and is better positioned under the narrative

2) Rights offering evaluation framework (Samsung Biologics)

  • Identify the offering price (≈ 1.33m KRW)
  • Assume “success/support” requires the market price to remain 15%–20% above the offering price
  • If the stock can’t hold that premium (market crashes), the rights-offering support logic weakens
  • If the current market price is already near/above the premium zone, the speaker implies it may be more rational to buy at market price rather than rely on the rights issue as a thesis catalyst

3) Market-regime condition: Alteogen vs Samsung Biologics

  • Alteogen
    • Prefer when KOSDAQ sentiment improves
    • Emphasized trigger: ~870–880
  • Samsung Biologics (Samba)
    • Viewed as more comfortable/resilient
    • Potential upside may be slower than more sentiment-driven names

Explicit recommendations / cautions

What to buy (conditional)

  • KOSPI / CDMO fundamentals: prefer Samsung Biologics
  • KOSDAQ leadership: prefer Alteogen if KOSDAQ recovers, especially toward 870–880+ sentiment

They also state (in spirit) that in the “right market regime,” they would not abandon either—i.e., no expectation that one must get “crushed.”

Rights offering caution

Rights offering “success” depends on market stability. If the market collapses, the premium/support logic breaks, reducing the value of the thesis.

Portfolio risk management

  • Cap exposure: pharma/biotech <10% (personal example: ~7%)

Performance expectation caution

  • Alteogen’s upside is framed as dependent on KOSDAQ money flow
  • Therefore, it may not surge as sharply as some expect if sentiment lags

Disclosures / disclaimers

  • No explicit “not financial advice” disclaimer appears in the provided subtitles/text.

Presenters / sources

  • 소재민 (Jae-min So)
  • 테디 (Teddy)

Original video